Zhuhai, Aug. 30 (ChinaMil) -- The 37th National Pharmaceutical Industry Information Conference in 2020, hosted by China Pharmaceutical Industry Information Center, opened in Zhuhai, Guangdong Province. The conference released the "2019 Top 100 Chinese Pharmaceutical Industry List", which was closely watched by the industry. Yangzijiang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Yangzijiang Pharmaceutical") ranked first among the top 100 Chinese pharmaceutical industry, ranking first for six consecutive years. Guangzhou Pharmaceutical Group Co., Ltd. and China Pharmaceutical Group Co., Ltd. ranked second and third. At the same time, Yangzijiang Pharmaceutical also won the title of "2020 China Pharmaceutical R&D Product Line Best Industrial Enterprise".

The top 100 list of China's pharmaceutical industry reflects the economic performance of China's pharmaceutical industry and is based on the annual Chinese pharmaceutical statistical report published by the Ministry of Industry and Information Technology (MIIT). In general, "2019 Chinese pharmaceutical industry top 100 list" top ten enterprises significant change, billions of cluster expansion and upgrading: there are 7 new enterprises, the number of enterprises over billions of new 5, a total of 27.

According to the statistics and analysis of China Pharmaceutical Industry Information Center, "the top 100 companies in China's pharmaceutical industry in 2019 continued their strong growth momentum, with their main business revenue scale reaching 929.64 billion yuan, with a growth rate of 10.7%. The income concentration rate of the top 100 enterprises' main business reached 35.6%. The threshold for the top 100 companies to enter the list has increased from 2.61 billion yuan in 2018 to 2.86 billion yuan.

Guo Wen, director of China Pharmaceutical Industry Information Center, said the top 100 list of China's pharmaceutical industry can inspire more companies to innovate, promote the transformation and upgrading of more enterprises, and promote the high-quality development of China's pharmaceutical industry.

The theme of this annual meeting is "the power of innovation", focusing on the speculation and exploration of the new path of China's medical innovation and development in the post-epidemic period. "Held on the same day, the meeting after the outbreak time how to better safeguard the people's health requirements of the new" enterprise of good leaders plan for national innovation, cross-border integration ", "outstanding innovative companies talk about the development of Chinese medicine industry innovation path" three round-table BBS, representatives for a number of government agencies, industry experts and the industry together, for the pharmaceutical industry innovation development, Benefit people's healthy life.

In the fierce competition environment, how to maintain the innovation vitality of the top 100 enterprises?

Yangtze river pharmaceutical group chairman attended the roundtable BBS Xu Jingren said, Yangtze river pharmaceutical industry will continue to product innovation, quality, innovation, technology innovation, management innovation, deepen the structural reform, the supply side to build international first-class drug production quality management system for quality strategic direction and make longfeng hall of Chinese traditional medicine industrial park, promote Chinese standardization planting, Establish the whole process traceability system of traditional Chinese medicine, set up the big health industry at a high starting point, accelerate the pace of green manufacturing and intelligent manufacturing, fulfill social responsibilities, stimulate the surging power of high-quality development, and make unremitting efforts to provide health services for the common people.

It is reported that since its establishment nearly 50 years ago, Yangzijiang Pharmaceutical Co., Ltd. has been resonating with the national strategy, sticking to the main business of medicine, carrying forward the quality culture of "pharmaceutical for parents, pharmaceutical for loved ones", and meeting the health needs of the people with research and development and innovation achievements.